|
1
|
Katanoda K, Hori M, Matsuda T, Shibata A,
Nishino Y, Hattori M, Soda M, Ioka A, Sobue T and Nishimoto H: An
updated report on the trends in cancer incidence and mortality in
Japan, 1958-2013. Jpn J Clin Oncol. 45:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chia SK, Speers CH, Bryce CJ, Hayes MM and
Olivotto IA: Ten-year outcomes in a population-based cohort of
node-negative, lymphatic, and vascular invasion-negative early
breast cancers without adjuvant systemic therapies. J Clin Oncol.
22:1630–1637. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cianfrocca M and Goldstein LJ: Prognostic
and predictive factors in early-stage breast cancer. Oncologist.
9:606–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanrahan EO, Valero V, Gonzalez-Angulo AM
and Hortobagyi GN: Prognosis and management of patients with
node-negative invasive breast carcinoma that is 1 cm or smaller in
size (stage 1; T1a, bN0M0): A review of the literature. J Clin
Oncol. 24:2113–2122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murakami Y: Involvement of a cell adhesion
molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci.
96:543–552. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murakami Y: Functional cloning of a tumor
suppressor gene, TSLC1, in human non-small cell lung cancer.
Oncogene. 21:6936–6948. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuramochi M, Fukuhara H, Nobukuni T, Kanbe
T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura
T, et al: TSLC1 is a tumor-suppressor gene in human non-small-cell
lung cancer. Nat Genet. 27:427–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goto A, Niki T, Chi-Pin L, Matsubara D,
Murakami Y, Funata N and Fukayama M: Loss of TSLC1 expression in
lung adenocarcinoma: Relationships with histological subtypes, sex
and prognostic significance. Cancer Sci. 96:480–486. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hui AB, Lo KW, Kwong J, Lam EC, Chan SY,
Chow LS, Chan AS, Teo PM and Huang DP: Epigenetic inactivation of
TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog. 38:170–178.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Honda T, Tamura G, Waki T, Jin Z, Sato K,
Motoyama T, Kawata S, Kimura W, Nishizuka S and Murakami Y:
Hypermethylation of the TSLC1 gene promoter in primary gastric
cancers and gastric cancer cell lines. Jpn J Cancer Res.
93:857–860. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jansen M, Fukushima N, Rosty C, Walter K,
Altink R, Heek TV, Hruban R, Offerhaus JG and Goggins M: Aberrant
methylation of the 5′ CpG island of TSLC1 is common in pancreatic
ductal adenocarcinoma and is first manifest in high-grade PanlNs.
Cancer Biol Ther. 1:293–296. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fukuhara H, Kuramochi M, Fukami T,
Kasahara K, Furuhata M, Nobukuni T, Maruyama T, Isogai K, Sekiya T,
Shuin T, et al: Promoter methylation of TSLC1 and tumor suppression
by its gene product in human prostate cancer. Jpn J Cancer Res.
93:605–609. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Steenbergen RD, Kramer D, Braakhuis BJ,
Stern PL, Verheijen RH, Meijer CJ and Snijders PJ: TSLC1 gene
silencing in cervical cancer cell lines and cervical neoplasia. J
Natl Cancer Inst. 96:294–305. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takahashi Y, Iwai M, Kawai T, Arakawa A,
Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F and
Murakami Y: Aberrant expression of tumor suppressors CADM1 and 4.1B
in invasive lesions of primary breast cancer. Breast Cancer.
19:242–252. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jang SM, Han H, Jun YJ, Jang SH, Min KW,
Sim J, Ahn HI, Lee KH, Jang KS and Paik SS: Clinicopathological
significance of CADM4 expression, and its correlation with
expression of E-cadherin and Ki-67 in colorectal adenocarcinomas. J
Clin Pathol. 65:902–906. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jang SM, Sim J, Han H, Ahn HI, Kim H, Yi
K, Jun YJ, Rehman A, Chung MS, Jang K and Paik SS:
Clinicopathological significance of CADM4 expression in invasive
ductal carcinoma of the breast. J Clin Pathol. 66:681–686. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sobin LH and Compton CC: TNM seventh
edition: What's new, what's changed: communication from the
international union against cancer and the American joint committee
on cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sobin LH, Gospodarowicz MK and Wittekind
Ch: International Union Against Cancer (UICC) TNM Classification of
Malignant Tumors. 7th. Wiley-Blackwell; Oxford, UK: 2009
|
|
20
|
Nagata M, Sakurai-Yageta M, Yamada D, Goto
A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y and
Murakami Y: Aberrations of a cell adhesion molecule CADM4 in renal
clear cell carcinoma. Int J Cancer. 130:1329–1337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saito M, Matsuzaki M, Sakuma T, Katagata
N, Watanabe F, Yamaguchi Y, Schetter AJ, Takenoshita S and Nomizu
T: Clinicopathological study of non-palpable familial breast cancer
detected by screening mammography and diagnosed as DCIS. Breast
Cancer. 21:140–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wikman H, Westphal L, Schmid F, Pollari S,
Kropidlowski J, Sielaff-Frimpong B, Glatzel M, Matschke J, Westphal
M, Iljin K, et al: Loss of CADM1 expression is associated with poor
prognosis and brain metastasis in breast cancer patients.
Oncotarget. 5:3076–3087. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Masuda M, Kikuchi S, Maruyama T,
Sakurai-Yageta M, Williams YN, Ghosh HP and Murakami Y: Tumor
suppressor in lung cancer (TSLC)1 suppresses epithelial cell
scattering and tubulogenesis. J Biol Chem. 280:42164–42171. 2005.
View Article : Google Scholar : PubMed/NCBI
|
